logo

Cidara Therapeutics, Inc. (CDTX)



Trade CDTX now with
  Date
  Headline
7/29/2019 7:11:26 AM Cidara Therapeutics Reports Positive Topline Results In Phase 2 STRIVE B Trial Of Antifungal Rezafungin
5/17/2019 6:24:31 AM Wedbush Cuts Cidara Therapeutics, Inc. (CDTX) To Neutral From Outperform With $2 Down From $7 Price Target
12/3/2018 8:01:31 AM Cidara Therapeutics Names James Levine CFO
11/9/2018 7:41:43 AM Wedbush Is Increasing Cidara Therapeutics, Inc. (CDTX) FY18 Estimate To -2.96 From -3.25
11/9/2018 7:41:18 AM Wedbush Is Increasing Cidara Therapeutics, Inc. (CDTX) Q4 18 Estimate To -0.54 From -0.67
10/4/2018 8:07:54 AM Cidara Therapeutics Presents Results From Phase 2 STRIVE Trial Of Rezafungin At IDWeek 2018;met All Primary Endpoints
9/27/2018 8:07:57 AM Cidara Therapeutics Initiates Phase 3 Trial Of Lead Antifungal Rezafungin For Invasive Candida Infections
9/25/2018 8:05:19 AM Cidara Therapeutics: FDA Grants QIDP And Fast Track Designations To Rezafungin Prophylaxis Development Program
9/12/2018 4:02:30 PM Cidara Therapeutics Appoints David Gollaher To Board Of Directors
6/15/2018 8:06:53 AM Cidara Therapeutics Announces Oral Presentations On Rezafungin
5/23/2018 12:16:30 PM Wedbush Is Increasing Cidara Therapeutics, Inc. (CDTX) FY18 Estimate To -2.49 From -2.51
5/23/2018 12:16:16 PM Wedbush Is Cutting Cidara Therapeutics, Inc. (CDTX) Q4 18 Estimate To -0.57 From -0.55
5/23/2018 12:16:03 PM Wedbush Is Cutting Cidara Therapeutics, Inc. (CDTX) Q3 18 Estimate To -0.56 From -0.54
5/23/2018 12:12:44 PM Wedbush Is Increasing Cidara Therapeutics, Inc. (CDTX) Q2 18 Estimate To -0.55 From -0.72
5/23/2018 6:18:04 AM WBB Securities Ups Cidara Therapeutics, Inc. (CDTX) To Speculative Buy From Hold With $6.25 Price Target
5/21/2018 8:17:04 AM Cidara Therapeutics And Rutgers University Awarded $5.5 Million Grant From NIH
3/19/2018 7:31:25 AM Cidara Therapeutics Reports Positive Topline Results From Phase 2 STRIVE Trial Of Lead Antifungal Rezafungin